Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

盘后交易 12-16 18:13:41 EST

78.37

-1.39

-1.74%

盘后78.37

+0.000.00%

17:35 EST

最高79.56	最低77.16	成交量195.97万
今开79.41	昨收79.76	日振幅3.01%
总市值126.94亿	流通市值126.18亿	总股本1.62亿
成交额1.53亿	换手率1.22%	流通股本1.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":78.37,"timestamp":1765918800000,"preClose":79.76,"halted":0,"volume":1959721,"hourTrading":{"tag":"盘后","latestPrice":78.37,"preClose":78.37,"latestTime":"17:35 EST","volume":70499,"amount":5525009.44996,"timestamp":1765924554845},"delay":0,"floatShares":161000000,"shares":161974393,"eps":-1.613241,"marketStatus":"盘后交易","change":-1.39,"latestTime":"12-16 18:13:41 EST","open":79.41,"high":79.555,"low":77.155,"amount":153266095.13452,"amplitude":0.03009,"askPrice":79.9,"askSize":25,"bidPrice":78.37,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.613241,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765933200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":79.76,"preHourTrading":{"tag":"盘前","latestPrice":79.63,"preClose":79.76,"latestTime":"09:25 EST","volume":1186,"amount":94686.13644,"timestamp":1765895100015},"postHourTrading":{"tag":"盘后","latestPrice":78.37,"preClose":78.37,"latestTime":"17:35 EST","volume":70499,"amount":5525009.44996,"timestamp":1765924554845},"volumeRatio":0.977478,"impliedVol":0.4523,"impliedVolPercentile":0.548},"requestUrl":"/m/hq/s/IONS/wiki","defaultTab":"wiki","newsList":[{"id":"1172421919","title":"Ionis宣布拟议可转换债券发行以再融资2026年可转换债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1172421919","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172421919?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:25","pubTimestamp":1763573107,"startTime":"0","endTime":"0","summary":"11月12日消息 - Ionis Pharmaceuticals Inc ::*IONIS宣布拟议可转换债券发行以再融资2026年可转换债券*IONIS PHARMACEUTICALS INC - 将发行7亿美元可转换债券，到期时间为2030年*IONIS PHARMACEUTICALS INC - 授予额外7000万美元债券的选择权","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1158847363","title":"Dawnzera™（Donidalorsen）获得CHMP积极意见，推荐在欧盟批准治疗遗传性血管水肿（HAE）","url":"https://stock-news.laohu8.com/highlight/detail?id=1158847363","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158847363?lang=zh_cn&edition=full","pubTime":"2025-11-14 20:01","pubTimestamp":1763121688,"startTime":"0","endTime":"0","summary":"Dawnzera™（Donidalorsen）获得CHMP的积极意见，建议在欧盟批准用于治疗遗传性血管水肿（HAE）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1159503918","title":"Ionis Pharmaceuticals Inc：定价7亿美元的2030年到期0.00%可转换高级债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1159503918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159503918?lang=zh_cn&edition=full","pubTime":"2025-11-13 13:40","pubTimestamp":1763012431,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals Inc：定价7亿美元的2030年到期0.00%可转换高级债券","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1191555721","title":"Ionis Pharmaceuticals股价在盘后上涨3.2%；宣布拟定可转换债券发行以再融资2026年可转换票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1191555721","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191555721?lang=zh_cn&edition=full","pubTime":"2025-11-12 05:38","pubTimestamp":1762897106,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals股价在盘后上涨3.2%；宣布拟定可转换债券发行以再融资2026年可转换票据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1172347027","title":"Ionis Pharmaceuticals：预计产品REV将迎来增长，新增合作伙伴REV助力公司在2028年实现现金流持平","url":"https://stock-news.laohu8.com/highlight/detail?id=1172347027","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172347027?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:11","pubTimestamp":1761736303,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals：预计产品REV将迎来增长，新增合作伙伴REV助力公司在2028年实现现金流持平","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1123195233","title":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1123195233","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123195233?lang=zh_cn&edition=full","pubTime":"2025-09-18 19:41","pubTimestamp":1758195688,"startTime":"0","endTime":"0","summary":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4588","LU0109394709.USD","BK4139","IE00B894F039.SGD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BIIB","BK4533","BK4532","LU0889565916.HKD","LU0234570918.USD","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"1135242848","title":"BMO将Ionis Pharmaceuticals评级从市场表现上调至跑赢大盘，目标价从40美元上调至70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135242848","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135242848?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:01","pubTimestamp":1756897303,"startTime":"0","endTime":"0","summary":"BMO将Ionis Pharmaceuticals的评级从市场表现上调至跑赢大盘，同时将目标价从40美元大幅上调至70美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1197561614","title":"Ionis Pharmaceuticals高管表示急性胰腺炎患者平均住院17天，支付方成本高昂","url":"https://stock-news.laohu8.com/highlight/detail?id=1197561614","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197561614?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:16","pubTimestamp":1756818976,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals高管表示，急性胰腺炎患者平均住院时间长达17天，这对支付方来说成本非常高昂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1180606351","title":"Ionis Pharmaceuticals高管：严重高甘油三酯血症适应症获批时将公布定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180606351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180606351?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:07","pubTimestamp":1756818424,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals公司高管表示，该公司将在其严重高甘油三酯血症治疗适应症获得监管批准时公布相关药物的定价信息。这一表态显示该公司正在为其治疗严重高甘油三酯血症的药物制定市场准入策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1120167759","title":"Ionis Pharmaceuticals高管表示Olezarsen有潜力为患者提供每月使用自动注射器自我给药的便利性 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1120167759","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120167759?lang=zh_cn&edition=full","pubTime":"2025-09-02 20:56","pubTimestamp":1756817811,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals高管表示Olezarsen有潜力为患者提供每月使用自动注射器自我给药的便利性 - 电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1133437325","title":"Ionis Pharmaceuticals：Olezarsen治疗严重高甘油三酯血症患者的关键3期Core和Core2研究获得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1133437325","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133437325?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:24","pubTimestamp":1756812253,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布，其药物Olezarsen在治疗严重高甘油三酯血症患者的关键3期Core和Core2研究中取得积极的顶线结果。这一研究成果为该公司在代谢性疾病治疗领域的发展提供了重要支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1123660220","title":"Ionis Pharmaceuticals：Olezarsen达到减少急性胰腺炎事件的次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1123660220","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123660220?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:12","pubTimestamp":1756811553,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals：Olezarsen达到减少急性胰腺炎事件的次要终点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1197389364","title":"Ionis Pharmaceuticals宣布Olezarsen三期临床研究取得积极结果 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1197389364","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197389364?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:08","pubTimestamp":1756811300,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布其药物Olezarsen的三期临床研究取得积极结果，该消息通过SEC文件披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1126122455","title":"Dawnzera™（多尼达洛森）获美国批准，成为首个也是唯一的RNA靶向遗传性血管水肿预防治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1126122455","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126122455?lang=zh_cn&edition=full","pubTime":"2025-08-21 23:46","pubTimestamp":1755791181,"startTime":"0","endTime":"0","summary":"Dawnzera™（多尼达洛森）已在美国获得批准，成为首个也是唯一一款针对遗传性血管水肿的RNA靶向预防性治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1110607632","title":"异动解读 | Ionis制药盘中大跌5.02%，与摩根士丹利\"买入\"评级形成反差","url":"https://stock-news.laohu8.com/highlight/detail?id=1110607632","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110607632?lang=zh_cn&edition=full","pubTime":"2025-08-07 02:42","pubTimestamp":1754505765,"startTime":"0","endTime":"0","summary":"周三盘中，RNA疗法领先企业Ionis Pharmaceuticals股价出现显著下跌，跌幅高达5.02%，引发市场关注。这一走势与近期该公司的利好消息形成鲜明对比，令投资者感到困惑。近期，Ionis Pharmaceuticals发布了强劲的第二季度业绩报告，展现了公司良好的发展势头。基于这些积极因素，摩根士丹利分析师迈克尔·乌尔茨将Ionis的评级上调至\"买入\"，并给出62美元的目标价，暗示约45%的潜在上涨空间。然而，尽管有这些利好消息支撑，Ionis的股价仍然出现大幅下跌。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IONS"],"gpt_icon":0},{"id":"2557480325","title":"RNA疗法先锋Ionis Pharmaceuticals(IONS.US)亮眼财报引爆机构唱多 大摩上调至“买入”看涨45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557480325","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557480325?lang=zh_cn&edition=full","pubTime":"2025-08-06 15:21","pubTimestamp":1754464889,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国生物科技公司Ionis Pharmaceuticals近期引起市场关注，该公司市值达68亿美元，专注研发RNA靶向疗法，用于治疗由基因或生化调节异常引发的疾病。截至目前，Ionis股价今年已累计上涨21.5%，表现远超大盘。富国银行分析师Yanan Zhu在Ionis公布强劲的第二季度业绩后，维持对该股的“买入”评级及77美元的目标价。该行表示，Ionis的业绩既体现了营收增长势头，也彰显了运营纪律性。总体而言，在华尔街，IONS股票维持“适度买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1326259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IONS","RNA"],"gpt_icon":0},{"id":"1175742599","title":"Ionis Pharmaceuticals 2025财年Q2业绩会总结及问答精华：Trimgolta表现强劲，未来多项产品上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1175742599","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175742599?lang=zh_cn&edition=full","pubTime":"2025-07-31 05:19","pubTimestamp":1753910378,"startTime":"0","endTime":"0","summary":"管理层强调，Trimgolta的报销趋势支持临床诊断和基因确认患者的覆盖，且绝大多数患者无需自付费用。Donidalorsen预计将在8月21日获得FDA批准，计划立即启动市场推广。Trimgolta产品销售额为1900万美元，环比增长三倍。问题1：Trimgolta在FCS市场的表现如何？Ionis Pharmaceuticals在2025财年第二季度表现强劲，Trimgolta的成功上市和研发合作收入推动了显著增长。公司对未来的产品上市充满信心，包括Donidalorsen和Olezarsen等潜在重磅产品。未来的多项数据发布和产品上市将进一步巩固其市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"1119812565","title":"异动解读 | Ionis Pharmaceuticals季度业绩超预期，股价盘中大涨8.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119812565","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119812565?lang=zh_cn&edition=full","pubTime":"2025-07-30 21:46","pubTimestamp":1753883178,"startTime":"0","endTime":"0","summary":"周三盘中，Ionis Pharmaceuticals, Inc股价大涨8.53%，引起市场广泛关注。这一显著涨幅主要源于公司发布的超预期季度财报。根据最新公布的财报，Ionis Pharmaceuticals截至6月30日的季度调整后每股收益为70美分，远超分析师预期的亏损43美分。值得注意的是，Ionis Pharmaceuticals股价本季度已上涨5.0%，今年迄今为止累计上涨18.6%。这些因素共同推动了投资者的买入热情，导致股价今日大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IONS"],"gpt_icon":0},{"id":"2555477360","title":"Ionis Pharmaceuticals, Inc.盘中异动 股价大涨8.28%报44.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555477360","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555477360?lang=zh_cn&edition=full","pubTime":"2025-07-30 21:32","pubTimestamp":1753882351,"startTime":"0","endTime":"0","summary":"北京时间2025年07月30日21时32分，Ionis Pharmaceuticals, Inc.股票出现异动，股价快速拉升8.28%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.54%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730213231a46bb4d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730213231a46bb4d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2548818467","title":"Ionis Pharmaceuticals, Inc.盘中异动 急速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548818467","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548818467?lang=zh_cn&edition=full","pubTime":"2025-07-02 22:02","pubTimestamp":1751464955,"startTime":"0","endTime":"0","summary":"北京时间2025年07月02日22时02分，Ionis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.07%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070222023597975e76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070222023597975e76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionispharma.com","stockEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.1147},{"period":"3month","weight":0.3008},{"period":"6month","weight":1.1551},{"period":"1year","weight":1.1786},{"period":"ytd","weight":1.2815}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司在反义药物发明和开发上处于行业领先地位，利用新药研发平台，公司研发了大量的一流药品。反义技术在基因学和药物之间打开了一条通道。凭着公司高效多产的药物研发平台，公司可以用反义药物拓展自身及其合作伙伴的药物种类，满足大量的药物需求。公司的策略是做公司最擅长的事--寻找独特的反义药物并开发这些药物，使其成为关键的临床值转折点。公司发明并进行新药早期研究，然后将药物授权给合作伙伴。公司通过把药物交给领先的制药公司进行后期开发来实现药物的最大价值，如Biogen Idec公司、百时美施贵宝公司、 健赞公司、赛诺菲公司、葛兰素史克公司和礼来制药公司。 该公司的旗舰产品 KYNAMRO，正朝着市场上家族性高胆固醇血症患者迈进。 该公司于1989年在美国加州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.026725},{"month":2,"riseRate":0.5,"avgChangeRate":-0.015083},{"month":3,"riseRate":0.3,"avgChangeRate":-0.028033},{"month":4,"riseRate":0.4,"avgChangeRate":0.018094},{"month":5,"riseRate":0.4,"avgChangeRate":-0.049558},{"month":6,"riseRate":0.8,"avgChangeRate":0.059464},{"month":7,"riseRate":0.8,"avgChangeRate":0.041363},{"month":8,"riseRate":0.5,"avgChangeRate":0.012224},{"month":9,"riseRate":0.5,"avgChangeRate":0.051342},{"month":10,"riseRate":0.2,"avgChangeRate":-0.026479},{"month":11,"riseRate":0.6,"avgChangeRate":0.097251},{"month":12,"riseRate":0.4,"avgChangeRate":0.00298}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}